Increased CD4+ helper and CD8+ effector T cell infiltration, reduced Tregs and downregulated PD-L1 expression on cancer cells have been reported in FGFR2- and p53-mutated lung cancer mouse models treated with erdafitinib in combination with anti-PD-1 therapy [105]. This evidence concerns the gene PDCD1 and cancer.